Mr. Patrick VRIJLANDT, Netherlands

Patrick Vrijlandt works at the Netherlands Medicines Evaluation Board since 2013, primarily involved in the assessment of scientific advice and marketing authorization applications for cardiovascular and metabolic products. He is an alternate member of the Committee for Human Medicinal Products (CHMP) at the European Medicines Agency (EMA) in Amsterdam since 2023.

He studied medicine in Groningen and became an internist in 2001. He further specialized in infectious diseases in Nijmegen and has a Diploma in Pharmaceutical Medicine from Basel. His clinical experience from working in small, large and academic hospitals includes cardiovascular and intensive care medicine, infectious diseases, endocrinology, hematology and care for elderly patients. Before joining the MEB, he worked at a clinical pharmacology unit specializing in phase 1 and 2 drug development. His current research focus is gender differences in the safety of medicinal products.